SERUM AND INTRACELLULAR DETECTION OF CYTOKINES IN PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS

被引:0
|
作者
ROCCATELLO, D
FORMICA, M
CAVALLI, G
QUATTROCCHIO, G
AIMO, G
POLLONI, R
AMPRIMO, MC
MOLINO, A
MARTINA, G
ISIDORO, C
MAZENGO, M
COPPO, R
SENA, LM
PICCOLI, G
机构
[1] OSPED G BOSCO,SERV FARM,TURIN,ITALY
[2] OSPED SAN FIOVANNI TORINO,RADIOIMMUNOL LAB,TURIN,ITALY
[3] OSPED G BOSCO,IMMUNOEMATOL LAB,TURIN,ITALY
[4] UNIV TURIN,INST NEFROUROL & PATOL GEN,I-10124 TURIN,ITALY
关键词
TUMOR NECROSIS FACTOR; INTERLEUKIN-2; RECEPTOR; NEOPTERIN; DIALYSIS MEMBRANES; SHAM DIALYSIS; MONOCYTES;
D O I
暂无
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Tumor necrosis factor (TNF) was detected, before and after dialysis, in sera from 69 patients and, at various times during dialysis, in 28 patients carefully selected for the absence of intercurrent illness. Blood samples were also sequentially collected for separation of monocytes, and cells were sonicated to detect intracellular TNF. Compared with serum levels obtained from 41 healthy subjects, basal TNF values of the unselected group of 69 patients were significantly higher (p < 0.01), independent of the dialyzer membrane. A significant increase in TNF levels by the end of dialysis was found only with Cuprophan (p < 0.01). In the selected group of 28 patients, no significant changes in TNF values were observed in sequential samples. However, a significant increase of intramonocyte TNF levels was found in Cuprophan patients (p < 0.025). Soluble interleukin-2 receptor (IL-2R) levels, measured in parallel in sera from unselected and selected patients, were found to be very much higher than healthy controls without significant changes during the dialysis procedure. While the diverse profiles of TNF obtained from differently selected patients suggest that mechanisms other than membrane biocompatibility play a role in the appearance of these low cytokine levels, the possible nature of uremic toxin for soluble IL-2R can be envisaged by detection in dialysis patients.
引用
收藏
页码:131 / 140
页数:10
相关论文
共 50 条
  • [1] SERUM BIOTIN LEVELS IN PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS
    LIVANIOU, E
    EVANGELATOS, GP
    ITHAKISSIOS, DS
    YATZIDIS, H
    KOUTSICOS, DC
    NEPHRON, 1987, 46 (03): : 331 - 332
  • [2] SERUM ASCORBIC-ACID IN PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS
    PONKA, A
    KUHLBACK, B
    ACTA MEDICA SCANDINAVICA, 1983, 213 (04): : 305 - 307
  • [3] SEPTICEMIA IN PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS
    BENHAMIDA, M
    HACHICHA, J
    CHAABOUNI, MN
    JARRAYA, A
    ANNALES DE MEDECINE INTERNE, 1989, 140 (02): : 99 - 101
  • [4] VANADIUM IN PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS
    HOSOKAWA, S
    YOSHIDA, O
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1989, 4 (04) : 282 - 284
  • [5] SERUM FERRITIN IN PATIENTS ON CHRONIC-HEMODIALYSIS
    PATERSON, AD
    GRAIL, A
    ANASTASSIADES, E
    PLATTS, MM
    HANCOCK, BW
    CLINICAL SCIENCE, 1980, 59 (03) : P10 - P10
  • [6] MENSTRUAL DYSFUNCTION IN PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS
    PEREZ, RJ
    LIPNER, H
    FERTILITY AND STERILITY, 1977, 28 (03) : 374 - 374
  • [7] RANITIDINE ACCUMULATION IN PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS
    COMSTOCK, TJ
    SICA, DA
    STONE, S
    DAVIS, J
    GARNETT, WR
    KARNES, HT
    WARNER, CW
    JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (12): : 1081 - 1085
  • [8] CELLULAR IMMUNOLOGY IN PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS
    STRUTZ, F
    RISLER, T
    HAIST, K
    BOSS, C
    ERLEY, C
    SKROCH, D
    MULLER, GA
    KIDNEY INTERNATIONAL, 1992, 41 (02) : 495 - 495
  • [9] MENSTRUAL DYSFUNCTION OF PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS
    PEREZ, RJ
    LIPNER, H
    ABDULLA, N
    CICOTTO, S
    ABRAMS, M
    OBSTETRICS AND GYNECOLOGY, 1978, 51 (05): : 552 - 555
  • [10] SERUM LIPOPROTEIN(A) AS AN INDEPENDENT CARDIOVASCULAR RISK FACTOR FOR PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS
    DOCCI, D
    MANZONI, G
    BALDRATI, L
    CAPPONCINI, C
    NERI, L
    FELETTI, C
    NEPHRON, 1995, 69 (02): : 195 - 195